02/04/13 -- International Stem Cell Corporation (OTCQB: ISCO)
(www.internationalstemcell.com) (ISCO or the Company) a California-based biotechnology
company, today announced positive 12-week results from its pre-clinical in vivo
Parkinson's disease study. The primary goal of this behavioral study was to demonstrate
the therapeutic benefits of neuronal cells derived from human parthenogenetic stem cell
(hpSC) line in a rat model of Parkinson's disease (PD).